IIA
ALXN

IPG Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

IPG Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,500
Closed -$904K – 185
2018
Q3 		$904K Sell
6,500
-200
-3% -$25.1K 0.29% 53
2018
Q2 		$832K Sell
6,700
-1,300
-16% -$152K 0.29% 51
2018
Q1 		$892K Buy
+8,000
New +$956K 0.29% 48
2017
Q4 		– Sell
-5,750
Closed -$807K – 172
2017
Q3 		$807K Buy
5,750
+4,040
+236% +$549K 0.28% 52
2017
Q2 		$208K Buy
+1,710
New +$199K 0.08% 122
2016
Q1 		– Sell
-1,800
Closed -$343K – 135
2015
Q4 		$343K Buy
+1,800
New +$314K 0.16% 78
2015
Q1 		– Sell
-1,935
Closed -$358K – 143
2014
Q4 		$358K Buy
+1,935
New +$359K 0.14% 77

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

IPG Investment Advisors's ALXN Position: Q4 2018 in Review

IPG Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 6,500 shares — an estimated $904K sold.

IPG Investment Advisors first reported a position in ALXN in Q4 2014 and held it in 7 quarters. The position peaked at $904K in Q3 2018. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • IPG Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • IPG Investment Advisors sold 6,500 Alexion Pharmaceuticals shares in Q4 2018, an estimated $904K.
  • IPG Investment Advisors first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 7 quarters.
  • IPG Investment Advisors's Alexion Pharmaceuticals position peaked at $904K in Q3 2018.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on IPG Investment Advisors's 13F filing for Q4 2018, filed 1 Feb 2019.